Health care
GILD Gilead Sciences
- Price
- $169.73
- This month
- −0.6%
- Market value
- $213B
- As of
- 12 Nov 2026
Stock score
Top fifth of the group
Ranks 1 of 70
How much to trust this score?
Since 2012, companies scoring 80–100 beat the S&P 500 over the next year 53% of the time. A coin flip is 50%.
The typical result was +1.4 pts against the index, and one in five ended outside −27 pts to +41 pts. Based on 2,195 past company-months. This score summarises public filings; it is not a forecast.
Score breakdown
Each measure is ranked against the other 69 companies: 100 is the best in the group, 50 the middle. The score ranks the average of the five.
Profitability
How much does it earn from what it has?
Return on assets 14.4%Net margin 28.9%83How it’s worked out
Measure Value Rank in group Formula Return on assets 14.4% 83 Net income ÷ total assets Net margin 28.9% 84 Net income ÷ revenue Growth
How fast is the business growing?
Revenue growth, 3 years 2.6%Earnings per share growth, 3 years 23.1%60How it’s worked out
Measure Value Rank in group Formula Revenue growth, 3 years 2.6% 45 Yearly rate from revenue three annual reports ago Earnings per share growth, 3 years 23.1% 75 Yearly rate from earnings per share three reports ago, split-adjusted Value
How much do you pay for its profit and cash?
Price to earnings 25.0×Free cash flow yield 4.4%67How it’s worked out
Measure Value Rank in group Formula Price to earnings 25.0× 64 Market value ÷ net income; ranked lower is better, and a loss ranks last Free cash flow yield 4.4% 71 (Operating cash flow − capital spending) ÷ market value Balance sheet
How much could it withstand?
Liabilities ÷ assets 61.5%Current ratio 1.5565How it’s worked out
Measure Value Rank in group Formula Liabilities ÷ assets 61.5% 54 Total liabilities ÷ total assets; lower is safer Current ratio 1.55 76 Current assets ÷ current liabilities Momentum
How has the share price moved?
Total return, 6 months 31.3%Total return, 12 months 45.2%85How it’s worked out
Measure Value Rank in group Formula Total return, 6 months 31.3% 88 Change in price plus dividends over 6 months Total return, 12 months 45.2% 81 Change in price plus dividends over 12 months
Figures from the 2025 annual report (10-K), filed 24 Feb 2026. View the filing on SEC.gov ↗ Return on equity, for reference: 37.5%.
Score over time
Each month-end since Jan 2012, using only the filings and prices public that day.
Track record by score
Share of companies that beat the S&P 500 over the next year, 2012–2025. This score’s range is highlighted.